Production of recombinant woodchuck IFNalpha and development of monoclonal antibodies
Palabras clave : 
2',5'-Oligoadenylate Synthetase/drug effects
Antibodies, Monoclonal/biosynthesis
Hepatitis B/immunology
Hepatitis B Antibodies/biosynthesis
Fecha de publicación: 
Editorial : 
Mary Ann Liebert
Berraondo P, Crettaz J, Ochoa L, Vales A, Ruiz J, Prieto J, et al. Production of recombinant woodchuck IFNalpha and development of monoclonal antibodies. J Interferon Cytokine Res 2009 Feb;29(2):75-82.
Interferon alpha (IFNalpha) is the first line treatment for chronic hepatitis B and C. In order to test new IFNalpha delivery systems and investigate the function of this cytokine in the woodchuck model, the best animal model of chronic hepatitis B, we produced and purified recombinant woodchuck IFNalpha and used it to produce monoclonal antibodies. wIFNalpha5 was cloned in a prokaryotic expression system, expressed as His-tagged protein and then purified. The rwIFNalpha5 protein was found to induce STAT-3 phosphorylation, to enhance 2',5'-oligoadenylate synthetase mRNA levels and to possess a potent antiviral activity. Two monoclonal antibodies were obtained through immunization of rats with rwIFNalpha5. Both recognized rwIFNalpha5 in western blot analysis and one was able to neutralize the antiviral activity of the rwIFNalpha5 and lymphoblastoid IFNalpha preparations. Finally, a capture rwIFNalpha5 ELISA was developed using both antibodies. In summary, the tools generated in this study will allow different forms of IFNalpha delivery as well as different combination therapies in woodchuck hepatitis virus infection to be tested, thus providing useful information for the design of new strategies to treat chronic hepatitis B in humans.

Ficheros en este registro:
284,52 kB
Adobe PDF

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.